DFCM
SYRE icon

Dark Forest Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Dark Forest Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,733
Closed -$247K – 1333
2025
Q3 		$247K Buy
+14,733
New +$240K 0.01% 1059

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Dark Forest Capital Management's SYRE Position: Q4 2025 in Review

Dark Forest Capital Management sold out of Spyre Therapeutics (SYRE) in Q4 2025, closing a stake of 14,733 shares — an estimated $247K sold.

Dark Forest Capital Management first reported a position in SYRE in Q3 2025 and held it in 1 quarter. The position peaked at $247K in Q3 2025. 153 funds tracked by Wall St. Rank hold SYRE as of Q4 2025.

  • Dark Forest Capital Management reported no remaining Spyre Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Dark Forest Capital Management sold 14,733 Spyre Therapeutics shares in Q4 2025, an estimated $247K.
  • Dark Forest Capital Management first reported a position in Spyre Therapeutics in Q3 2025 and held it in 1 quarter.
  • Dark Forest Capital Management's Spyre Therapeutics position peaked at $247K in Q3 2025.
  • 153 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2025.

Based on Dark Forest Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.